Genitourinary System Carcinoma — Trials

Genitourinary System Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

4,919 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,501
Recruiting: 783
Ph III recruiting: 85
Growth YoY: +18.1%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (758)

clinicaltrialsPublishedShowing 2,001–2,050 of 2,131 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00523640	A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma	terminated	Phase 2	30	University of ChicagoOTHER	1	Feb 11, 2014	clinicaltrials
NCT01982487	Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission	withdrawn	Phase 1 / Phase 2	0	Roswell Park Cancer InstituteOTHER	0	Dec 18, 2013